The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study

Journal of the American Academy of Dermatology

Volumn 67, Issue 4, 2012, Pages 642-650

  Gottlieb, Alice B ^a   Kalb, Robert E ^b   Blauvelt, Andrew ^c   Heffernan, Michael P ^d   Sofen, Howard L ^e   Ferris, Laura Korb ^f   Kerdel, Francisco A ^g   Calabro, Stephen ^h   Wang, Jim ⁱ   Kerkmann, Urs ^j   Chevrier, Marc ^h  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Central Dermatology   (United States)

^e Dermatology Associates   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g Florida Academic Dermatology Centers   (United States)

^h Janssen Biotech Inc   (United States)

ⁱ JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^j Janssen Biologics   (Netherlands)

more..

Author keywords

anti tumor necrosis factor; etanercept; infliximab; nonresponder; psoriasis; sequential therapy; switch

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; DRUG ANTIBODY; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BURSITIS; CELLULITIS; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXTRAVASATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUSHING; GASTRITIS; HEART MUSCLE ISCHEMIA; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NEUTROPHIL COUNT; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; RATING SCALE; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TUBERCULOSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84866401186     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.10.020     Document Type: Article

References (30)

1. A. Di Cesare, P. Di Meglio, and F. Nestle The IL-23/Th17 axis in the immunopathogenesis of psoriasis J Invest Dermatol 129 2009 1339 1350
2. S. Kagami, H.L. Rizzo, J.J. Lee, Y. Koguchi, and A. Blauvelt Circulating Th17, Th22, and Th1 cells are increased in psoriasis J Invest Dermatol 130 2010 1373 1383
3. L.C. Zaba, M. Suarez-Farinas, J. Fuentes-Duculan, K.E. Nograles, E. Guttman-Yassky, and I. Cardinale Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes J Allergy Clin Immunol 124 2009 1022 1030
4. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, A. Wang Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
5. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi Etanercept Psoriasis Study Group A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
6. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
7. K. Reich, F.O. Nestle, K. Papp, J.-P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 366 2005 1367 1374
8. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31.e1 31.e15
9. K.E. Hansen, J.P. Hildebrand, M.C. Genovese, J.J. Cush, S. Patel, and D.A. Cooley The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis J Rheumatol 31 2004 1098 1102
10. R. van Vollenhoven, A. Harju, S. Brannemark, and L. Klareskog Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense Ann Rheum Dis 62 2003 1195 1198
11. R.F. van Vollenhoven Switching between biological agents Clin Exp Rheumatol 22 2004 S115 S121
12. D. Furst, N. Gaylis, V. Bray, E. Olech, D. Yocum, and J. Ritter Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study Ann Rheum Dis 66 2007 893 899
13. H.T.S. Ang, and S. Helfgott Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-α antagonists in patients with rheumatoid arthritis? J Rheumatol 30 2003 2315 2318
14. R. Bissonnette, C. Bolduc, Y. Poulin, L. Guenther, C.W. Lynde, and C. Maari Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept J Am Acad Dermatol 63 2010 228 234
15. K.A. Haitz, and R.E. Kalb Infliximab in the treatment of psoriasis in patients previously treated with etanercept J Am Acad Dermatol 57 2007 120 125
16. A. Mazzotta, M. Esposito, A. Costanzo, and S. Chimenti Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study Am J Clin Dermatol 10 2009 319 324
17. G. Pitarch, J.L. Sánchez-Carazo, L. Mahiques, and V. Oliver Efficacy of etanercept in psoriatic patients previously treated with infliximab Dermatology 216 2008 312 316
18. M. Papoutsaki, M.-S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, and A. Giunta Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics J Am Acad Dermatol 57 2007 269 275
19. J.-P. Ortonne, S. Chimenti, K. Reich, R. Gniadecki, P. Sprogel, and K. Unnebrink Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE J Eur Acad Dermatol Venereol 25 2011 1012 1020
20. B.E. Strober, Y. Poulin, F.A. Kerdel, R.G. Langley, Y. Gu, and S.R. Gupta Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study J Am Acad Dermatol 64 2011 671 681
21. Enbrel [etanercept prescribing information] 2009 Immunex Corp Thousand Oaks, CA
22. A.B. Gottlieb, U. Chaudhari, D. Baker, M. Perate, and L.T. Dooley The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison J Drugs Dermatol 3 2003 260 266
23. T. Fredricksson, and U. Pettersson Severe psoriasis: oral therapy with a new retinoid Dermatologica 157 1978 238 244
24. J. Schmitt, and G. Wozel The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis Dermatology 210 2005 194 199
25. R.H. Dworkin, D.C. Turk, K.W. Wyrwich, D. Beaton, C.S. Cleeland, and J.T. Farrar Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendation J Pain 9 2008 105 121
26. A.Y. Finlay, and G.K. Khan Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
27. D. Pathirana, A.D. Ormerod, P. Saiag, C. Smith, P.I. Spuls, and A. Nast European S3-guidelines on the systemic treatment of psoriasis vulgaris J Eur Acad Dermatol Venereol 23 2009 5 70
28. L. Yip, S. Harrison, and P. Foley From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis Australas J Dermatol 49 2008 152 155
29. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
30. S. Bremmer, A.S. Van Voorhees, S. Hsu, N.J. Korman, M. Lebwohl, and M. Young Obesity and psoriasis: from the Board of the Medical National Psoriasis Foundation J Am Acad Dermatol 63 2010 1058 1069